MBI Lab & Care is a leading institution in Taiwan’s medical research sector, specializing in non-pharmacological treatments for severe, treatment-resistant depression. The center employs advanced therapies such as repetitive transcranial magnetic stimulation (rTMS), traditional Chinese acupuncture, high-concentration unsaturated fatty acids, and photobiomodulation to enhance patient outcomes.
Through the integration of functional magnetic resonance imaging (fMRI), cognitive assessment analysis, molecular biology, animal studies, and cellular models, the lab has developed extensive expertise in conducting clinical trials for depression.
MBI Lab & Care collaborates closely with leading international research teams from the United Kingdom, the United States, Canada, Japan, Poland, Macau, and Germany, fostering global innovation in mental health research.
Key Research Areas:
Investigating the pathophysiology and pharmacological aspects of depression and other psychiatric disorders.
Developing innovative, integrative depression treatments, including Omega-3 unsaturated fatty acids, transcranial magnetic stimulation (TMS), photobiomodulation, traditional Chinese medicine, and lifestyle interventions.
Conducting neuroimaging studies to examine the impact of psychiatric disorders on brain function.
Advancing pharmacogenomic research to improve personalized treatment strategies in mental health.
Exploring cognitive function research to assess how psychiatric conditions affect cognitive performance.
Through the integration of functional magnetic resonance imaging (fMRI), cognitive assessment analysis, molecular biology, animal studies, and cellular models, the lab has developed extensive expertise in conducting clinical trials for depression.
MBI Lab & Care collaborates closely with leading international research teams from the United Kingdom, the United States, Canada, Japan, Poland, Macau, and Germany, fostering global innovation in mental health research.
Key Research Areas:
Investigating the pathophysiology and pharmacological aspects of depression and other psychiatric disorders.
Developing innovative, integrative depression treatments, including Omega-3 unsaturated fatty acids, transcranial magnetic stimulation (TMS), photobiomodulation, traditional Chinese medicine, and lifestyle interventions.
Conducting neuroimaging studies to examine the impact of psychiatric disorders on brain function.
Advancing pharmacogenomic research to improve personalized treatment strategies in mental health.
Exploring cognitive function research to assess how psychiatric conditions affect cognitive performance.
MBI Lab & Care oversees multiple ongoing clinical trials, led by experienced principal investigators, to explore new treatment approaches across various patient populations.
Target Participants:
Individuals diagnosed with severe depression
Adults with obesity
Individuals with insomnia
Children and adolescents with ADHD
Children and adolescents with obesity
Individuals experiencing long COVID symptoms
Research Applications:
Investigating the effects of high-concentration unsaturated fatty acids
Evaluating photobiomodulation therapy as a non-invasive treatment option
Conducting advanced brainwave analysis for improved diagnostics
Assessing heart rate variability (HRV) as a biomarker for mental health
Exploring wearable digital phenotype detection for personalized treatment approaches
Outcome Measures:
Symptom reduction in depression and related conditions
Improvements in quality of life
Identification of key biomarkers for mental health diagnostics
Advancements in digital phenotyping for personalized care
How to Get Involved:
[Become a Research Participant] → Participate in Research
[Support Clinical Trials] → Funding
[Explore Collaboration Opportunities] → Contact Us
Target Participants:
Individuals diagnosed with severe depression
Adults with obesity
Individuals with insomnia
Children and adolescents with ADHD
Children and adolescents with obesity
Individuals experiencing long COVID symptoms
Research Applications:
Investigating the effects of high-concentration unsaturated fatty acids
Evaluating photobiomodulation therapy as a non-invasive treatment option
Conducting advanced brainwave analysis for improved diagnostics
Assessing heart rate variability (HRV) as a biomarker for mental health
Exploring wearable digital phenotype detection for personalized treatment approaches
Outcome Measures:
Symptom reduction in depression and related conditions
Improvements in quality of life
Identification of key biomarkers for mental health diagnostics
Advancements in digital phenotyping for personalized care
How to Get Involved:
[Become a Research Participant] → Participate in Research
[Support Clinical Trials] → Funding
[Explore Collaboration Opportunities] → Contact Us
MBI Lab & Care actively partners with academic institutions, medical centers, and industry leaders worldwide to advance research in mental health diagnostics, treatment innovations, and non-pharmacological therapies. Our interdisciplinary approach fosters collaborative research that leads to tangible improvements in mental health care.
International Collaboration
Our partnerships extend across the United Kingdom, the United States, Canada, Japan, Poland, Macau, and Germany, working on joint research initiatives focused on:
Understanding the pathophysiology of depression and psychiatric disorders.
Developing next-generation treatment strategies, including:
– Functional MRI (fMRI) technology applications
– Pharmacogenomic research for precision psychiatry
– Omega-3 fatty acid adjunct therapy
– Through these global collaborations, MBI Lab & Care is contributing to significant advancements in mental health research.
Domestic Collaboration
Within Taiwan, MBI Lab & Care works closely with leading medical institutions, psychiatric research centers, and academic partners to:
Integrate clinical and foundational research for more effective treatments.
Develop personalized psychiatric treatment models tailored to Asian populations.
Collaborate on non-pharmacological interventions, including:
– Repetitive transcranial magnetic stimulation (rTMS)
– Photobiomodulation therapy
– Traditional Chinese acupuncture
– Lifestyle-based mental health interventions
– Leverage big data and artificial intelligence (AI) to improve precision medicine in psychiatry.
– Industry Collaboration & Clinical Trials
We work with global pharmaceutical companies, biotechnology firms, and mental health tech startups to conduct clinical trials for both pharmacological and non-pharmacological treatments. These partnerships help bridge the gap between scientific discoveries and real-world applications, improving treatment accessibility and effectiveness.
We welcome hospitals, academic research teams, and industry innovators to join us in developing the future of mental health care.
Collaboration Inquiries
For inquiries regarding research partnerships, clinical trials, or industry collaborations, contact our research team to explore mutually beneficial opportunities.
International Collaboration
Our partnerships extend across the United Kingdom, the United States, Canada, Japan, Poland, Macau, and Germany, working on joint research initiatives focused on:
Understanding the pathophysiology of depression and psychiatric disorders.
Developing next-generation treatment strategies, including:
– Functional MRI (fMRI) technology applications
– Pharmacogenomic research for precision psychiatry
– Omega-3 fatty acid adjunct therapy
– Through these global collaborations, MBI Lab & Care is contributing to significant advancements in mental health research.
Domestic Collaboration
Within Taiwan, MBI Lab & Care works closely with leading medical institutions, psychiatric research centers, and academic partners to:
Integrate clinical and foundational research for more effective treatments.
Develop personalized psychiatric treatment models tailored to Asian populations.
Collaborate on non-pharmacological interventions, including:
– Repetitive transcranial magnetic stimulation (rTMS)
– Photobiomodulation therapy
– Traditional Chinese acupuncture
– Lifestyle-based mental health interventions
– Leverage big data and artificial intelligence (AI) to improve precision medicine in psychiatry.
– Industry Collaboration & Clinical Trials
We work with global pharmaceutical companies, biotechnology firms, and mental health tech startups to conduct clinical trials for both pharmacological and non-pharmacological treatments. These partnerships help bridge the gap between scientific discoveries and real-world applications, improving treatment accessibility and effectiveness.
We welcome hospitals, academic research teams, and industry innovators to join us in developing the future of mental health care.
Collaboration Inquiries
For inquiries regarding research partnerships, clinical trials, or industry collaborations, contact our research team to explore mutually beneficial opportunities.